STOCK TITAN

Quest Diagnostics, Inc. - DGX STOCK NEWS

Welcome to our dedicated news page for Quest Diagnostics (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics's position in the market.

Rhea-AI Summary
Quest Diagnostics (DGX) launches novel prostate cancer biomarker test in collaboration with Envision Sciences, aiming to improve diagnosis and grading of prostate cancer. The new tissue-based test service utilizes Envision's proprietary biomarkers and technology to address the clinical need for identifying and differentiating aggressive prostate cancer cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) Named to 2023 Disability Equality Index Best Places to Work for Disability Inclusion by Disability: IN and AAPD, Recognized for Sixth Consecutive Year. Quest's commitment to disability inclusion and equality showcased through DiverseAbilities Employee Business Network and emphasis on neurodiversity, cancer support, and accessibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics has launched its first consumer-initiated genetic test called Genetic Insights. The test offers insights into potential risks of developing inheritable health conditions by analyzing 36 genes. It uses advanced next-generation sequencing technology and provides personalized health reports and access to genetic counseling. The test covers conditions such as breast and colon cancer, heart and blood disorders, and carrier status for cystic fibrosis, sickle cell anemia, and Tay-Sachs disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
Quest Diagnostics, Inc.

NYSE:DGX

DGX Rankings

DGX Stock Data

14.27B
109.71M
0.43%
91.73%
2.29%
Medical Laboratories
Health Care and Social Assistance
Link
US
Secaucus

About DGX

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator